Affinity Biologicals, a Manufacturer of Thrombosis and Hemostasis Research Products, Announces Involvement in the ISTH SSC 2016 Meeting

The 62nd Annual Meeting of the Scientific and Standardization Committee (SSC) of the International Society of Thrombosis and Hemostasis (ISTH) begins on May 25th in Montpelier, France, and will continue through to the 28th. Affinity Biologicals will participate in the event through a discussion of products with clients and networking with other researchers in the field. - May 14, 2016

Hemophilia Treatment ACE910 Bypasses Factor VIII Inhibitor in Affinity Biologicals Plasmas

Chugai Pharmaceutical's newly developed antibody ACE910 is a potential lifesaving treatment for Hemophilia A patients who have developed Factor VIII inhibitors. A first-in-human study (1) recently published by the American Society of Hematology indicates that ACE910 may be a safe and effective treatment for hemophilia A patients. - December 11, 2015

Product Spotlight: Introducing Factor V Coagulation Antibodies from Affinity Biologicals Inc.

The human heart is an amazing vessel that pumps blood throughout the body, but sometimes genetic mutations make it difficult for the cardiovascular system to function the way it should. Most people inherit the factor V protein gene, which promotes healthy blood clotting throughout the body. Unfortunately, some inherit the factor V Leiden gene, which does just the opposite and prevents blood from clotting normally. - November 30, 2015

Affinity Biologicals Inc. to Attend the International Society of Thrombosis & Hemostasis Congress/Exhibition in June

Later this month, Affinity Biologicals Inc., a research and diagnostics manufacturer based in Ontario, will be attending the International Society of Thrombosis and Hemostasis (ISTH) congress and exhibition in Toronto. - June 06, 2015

Affinity Biologicals Inc. Introduces Laboratories to the New Factor VII Kit to Their Line of Factor VIII Inhibitor Kits

Affinity Biologicals Inc. is excited to announce that in order improve quantitative thrombosis and hemostasis research they are introducing laboratories to the Factor VII Antigen Elisa Kit, a new addition to the existing Factor VIII Inhibitor Kits. - May 08, 2015

Affinity Biologicals Inc. Explains the Difference between Polyclonal vs Monoclonal Antibodies

As a provincially licensed research facility, a large portion of Affinity Biological Inc.’s work involves purifying proteins and developing assays. Currently, they manufacture 2 types of antibodies for research applications: polyclonals and monoclonals. - April 22, 2015

Affinity Biologicals Inc. Releases New Feature with Polyclonal Coagulation Antibodies Over Monoclonal Coagulation Antibodies for Quantitative Research

For over 28 years, Affinity Biologicals Inc. has been producing a diverse number of products for research and diagnostic purposes. - February 17, 2015

Affinity Biologicals Inc. Launches Their Debut VisuLize™ Factor VII Antigen – A Polyclonal Antibody Based ELISA Kit

As a licensed medical device manufacturer that is recognized by the US Food and Drug Administration, Health Canada, and European regulatory authorities, Affinity Biologicals Inc. is constantly striving to produce reliable reagents for various applications in the health science industry. - November 11, 2014

Affinity Biologicals Inc. to Showcase their Factor Deficient Plasmas for Hemostasis & Thrombosis Research at the MEDICA 2014 in Düsseldorf, Germany

On November 12, 2014 through to November 15, 2015, Affinity Biologicals Inc. will be attending the annual MEDICA trade fair in Düsseldorf, Germany to showcase their line of factor deficient/ factor depleted plasmas. - November 11, 2014

Affinity Biologicals Presents New Health Canada & CE Marked Plasmas for Diagnostic Use and Hemostasis Research in Canada & Europe

Affinity Biologicals Inc., a leading name in diagnostics and research, especially hemostasis research, has recently announced the launching of their new Factor Deficient Plasma page that features their new Health Canada and CE Marked plasmas. - August 29, 2014

Affinity Biologicals Introduce Upgraded Collection of VisuLize™ Antigen ELISA Kits

ELISA, otherwise known as the enzyme-linked immunosorbent assay, is a test that detects the presence of a certain substance, generally an antigen, by monitoring antibodies and colour change. - August 21, 2014

Affinity Biologicals Now Offers a Variety of Elisa Kits Aimed at Thrombosis Research

Significant New Innovations by Affinity Biologicals Promise to Greatly Extend Assay Sensitivity and ELISA’s Range of Capabilities - July 04, 2014

Launching an Improved Range of Visulize™ Antigen ELISA Kits, Affinity Biologicals Inc. Simplifies Quantitative Assays of Hemostasis and Thrombosis-Related Proteins

Affinity Biologicals Inc. Makes a Valuable Addition to the Family of ELISA Kits with VisuLize™ Antigen Kits - May 29, 2014

Affinity Biologicals Inc. Now Offers a Complete Range of VisuLize™ Antigen ELISA Kits for Human Plasma Sample Analysis

VisuLize™ Antigen ELISA kits by Affinity Biologicals Ontario are used to determine Factor VIII, IX, XI and TAFI antigens in human plasma samples. - March 26, 2014

Affinity Biologicals Inc. Has Become a Primary Manufacturer of Polyclonal Antibodies Used in Hemostasis & Thrombosis Research Around the World

Affinity Biologicals, the Ontario-based company has gradually become the primary manufacturer of Hemostasis & Thrombosis related polyclonal antibodies, which are delivered for research and diagnosis around the world. - March 12, 2014

Affinity Biologicals Inc. Expands Their Line of Polyclonal Antibody Based ELISA Kits

The Ontario based company Affinity Biologicals Inc. announces the launch of a new polyclonal antibody based Factor XI antigen ELISA kit. - February 20, 2014

Press Releases 1 - 16 of 16